Cargando…

Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(®)): data from the PATRO Adults study

BACKGROUND: To assess the safety (particularly the occurrence of malignancies) of growth hormone (GH) replacement (Omnitrope(®)) in adults with GH deficiency, using data from the ongoing PATRO Adults post-marketing surveillance study. METHODS: PATRO Adults is being conducted in hospitals and special...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beck-Peccoz, Paolo, Höybye, Charlotte, Murray, Robert D, Simsek, Suat, Zabransky, Markus, Zouater, Hichem, Stalla, Günter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491215/ https://www.ncbi.nlm.nih.gov/pubmed/32973992 http://dx.doi.org/10.1177/2042018820943377

Ejemplares similares

No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study
por: Beck-Peccoz, Paolo, et al.
Publicado: (2019)

SAT-437 The Patro Adults Study of Omnitrope® for the Treatment of Adult Patients with Growth Hormone Deficiency: Latest Safety Outcomes Including Diabetes Risk
por: Beck-Peccoz, Paolo, et al.
Publicado: (2019)

Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults)
por: Höybye, Charlotte, et al.
Publicado: (2021)

Safety and effectiveness of Omnitrope(®) (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data
por: Backeljauw, Philippe, et al.
Publicado: (2022)

Long-term safety and efficacy of Omnitrope®, a somatropin biosimilar, in children requiring growth hormone treatment: Italian interim analysis of the PATRO Children study
por: Iughetti, Lorenzo, et al.
Publicado: (2016)

Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies
por: Lundberg, Elena, et al.
Publicado: (2020)

Long-term safety and efficacy of Omnitrope(®) in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study
por: Ferone, D., et al.
Publicado: (2017)

SUN-255 PATRO Children, a Multi-Center, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope® in Children Requiring Growth Hormone Treatment: Comparing United States (US) and Rest of World (ROW) Data
por: Backeljauw, Philippe, et al.
Publicado: (2019)

SUN-254 A Long-Term, Phase IV Study of Omnitrope®, a Recombinant Human Growth Hormone (rhGH), in Short Children Born Small for Gestational Age (SGA)
por: Schwarz, Hans-Peter, et al.
Publicado: (2019)

Somatropin therapy in italian adults with growth hormone deficiency
por: Pricci, Flavia, et al.
Publicado: (2022)

Long-term follow up of carbohydrate metabolism and adverse events after termination of Omnitrope® treatment in children born small for gestational age
por: Walczak, Mieczyslaw, et al.
Publicado: (2021)

A Follow-up Study to Monitor Adult Height Among Spanish Children with Growth Hormone Deficiency Who Received Biosimilar Human Recombinant Growth Hormone (Omnitrope(®)) During a Phase III Clinical Trial
por: Borrás Pérez, Victoria, et al.
Publicado: (2015)

Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009–2014
por: Marcianò, Ilaria, et al.
Publicado: (2018)

Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
por: Fleseriu, Maria, et al.
Publicado: (2021)

Acceptability of the reusable SurePal™ self-injection device for Omnitrope(®) among pediatric patients: results from a questionnaire-based, cross-sectional, multicenter observational study
por: Partsch, Carl-Joachim, et al.
Publicado: (2015)

Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial
por: Maniatis, Aristides K., et al.
Publicado: (2022)

Evaluation of human growth hormone (somatropin) in socket healing: a split-mouth randomized controlled trial
por: Sleman, Nadim, et al.
Publicado: (2023)

Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
por: Rashid, Nazia, et al.
Publicado: (2014)

Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study
por: Maniatis, Aristides K, et al.
Publicado: (2022)

Ten years’ clinical experience with biosimilar human growth hormone: a review of efficacy data
por: López-Siguero, Juan Pedro, et al.
Publicado: (2017)

Ten years of clinical experience with biosimilar human growth hormone: a review of safety data
por: Borrás Pérez, Maria Victoria, et al.
Publicado: (2017)

Erratum to: Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
por: Rashid, Nazia, et al.
Publicado: (2014)

Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study
por: Deal, Cheri L, et al.
Publicado: (2022)

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways
por: Schiestl, Martin, et al.
Publicado: (2017)

Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
por: Frindik, J Paul, et al.
Publicado: (2010)

Optimized Signal Peptide for Secretory Expression of Human Recombinant Somatropin in E. coli
por: Ahmadi, Zeynab, et al.
Publicado: (2023)

Effect of Twine-arginine Translocation-signaling Fusion System and Chaperones Co-expression on Secretory Expression of Somatropin
por: Bagherinejad, Mohammad Reza, et al.
Publicado: (2018)

Osteometabolic profile and bone mass in the transition phase: ethnic differences in Brazilians treated with somatropin during childhood
por: Kuba, Valesca M., et al.
Publicado: (2022)

Current Status of Biosimilar Growth Hormone
por: Saenger, Paul
Publicado: (2009)

Time for a general approval of growth hormone treatment in adults with Prader–Willi syndrome
por: Höybye, Charlotte, et al.
Publicado: (2021)

Adding Ozone to Dextrose and Somatropin for Intra-articular Knee Prolotherapy: A Randomized Single-Blinded Controlled Trial
por: Imani, Farnad, et al.
Publicado: (2020)

Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study
por: Horikawa, Reiko, et al.
Publicado: (2022)

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency
por: Höybye, Charlotte, et al.
Publicado: (2019)

An Adapted Model for Transition to Adult Care in Young Adults with Prader–Willi Syndrome
por: Pedersen, Maria, et al.
Publicado: (2021)

Effects of Growth Hormone Treatment on Sleep-Related Parameters in Adults With Prader-Willi Syndrome
por: Shukur, Hasanain Hamid, et al.
Publicado: (2021)

Efficacy and Safety of Biosimilar Growth Hormone in Indian Children
por: Khadilkar, Vaman, et al.
Publicado: (2018)

Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas
por: Auer, Matthias K., et al.
Publicado: (2016)

PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
por: Biller, Beverly, et al.
Publicado: (2022)

Ten years of biosimilar recombinant human growth hormone in Europe
por: Saenger, Paul
Publicado: (2017)

PMON329 Survey of physician experience with once weekly somatrogon vs once daily somatropin regimen for the treatment of pediatric patients with growth hormone deficiency: results from a cross sectional, observational study
por: Gomez, Roy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dsg8qf68g1aovar0pgibr3fule